Abstract
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79% achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39% CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (Ara-C), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69% of patients in the induction phase and in 70% in the maintenance phase. Nineteen of 39 patients (49% remain in CR with a follow-up to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).
Original language | English (US) |
---|---|
Pages (from-to) | 291-296 |
Number of pages | 6 |
Journal | Leukemia and Lymphoma |
Volume | 15 |
Issue number | 3-4 |
DOIs | |
State | Published - 1994 |
Keywords
- CHOP/L-asparaginase regimen
- CNS prophylaxis
- Lymphoblastic
- Non-Hodgkin's lymphoma
- Phase II trial
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research